NCT04387227View on ClinicalTrials.gov

Pembrolizumab and Carboplatin for the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

22

Participants

Timeline

Start Date

March 18, 2021

Primary Completion Date

September 12, 2025

Study Completion Date

June 1, 2026

Conditions
Recurrent Fallopian Tube CarcinomaRecurrent Ovarian CarcinomaRecurrent Primary Peritoneal Carcinoma
Interventions
DRUG

Carboplatin

Given IV

BIOLOGICAL

Pembrolizumab

Given IV

PROCEDURE

Computed Tomography

Undergo CT

PROCEDURE

Magnetic Resonance Imaging

Undergo MRI

PROCEDURE

Biospecimen Collection

Undergo blood sample collection

Trial Locations (1)

98109

Fred Hutch/University of Washington Cancer Consortium, Seattle

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

collaborator

United States Department of Defense

FED

lead

University of Washington

OTHER